This study was undertaken to determine whether and how advanced glycation end products (AGE), senescent macroproteins accumulated in various tissues under hyperglycemic states, cause angiogenesis, the principal vascular derangement in diabetic microangiopathy. We first prepared AGE-bovine serum albumin (BSA) and anti-AGE antiserum using AGE-RNase A. Then AGE-BSA was administered to human skin microvascular endothelial cells in culture, and their growth was examined. The AGE-BSA, but not nonglycated BSA, was found to induce a statistically significant increase in the number of viable endothelial cells as well as their synthesis of DNA. The increase in DNA synthesis by AGE-BSA was abolished by anti-AGE antibodies. AGE-BSA also stimulated the tube formation of endothelial cells on Matrigel. We obtained the following evidence that it is vascular endothelial growth factor (VEGF) that mainly mediates the angiogenic activities of AGE. Glucose and other reducing sugars can react nonenzymatically with the amino groups of proteins to form reversible Schiff bases and, then, Amadori products. These early glycation products undergo further complex reactions such as rearrangement, dehydration, and condensation to become irreversibly crosslinked, heterogeneous fluorescent derivatives termed advanced glycation end products (AGE) 1 (1). The formation and accumulation of AGE in various tissues have been known to progress during normal aging and at an extremely accelerated rate in diabetes mellitus. This has been implicated in the development of diabetic micro-and macro-vascular complications (1), which may account for the disabilities and high mortality rate in patients with this disease (2).
Glucose and other reducing sugars can react nonenzymatically with the amino groups of proteins to form reversible Schiff bases and, then, Amadori products. These early glycation products undergo further complex reactions such as rearrangement, dehydration, and condensation to become irreversibly crosslinked, heterogeneous fluorescent derivatives termed advanced glycation end products (AGE) 1 (1) . The formation and accumulation of AGE in various tissues have been known to progress during normal aging and at an extremely accelerated rate in diabetes mellitus. This has been implicated in the development of diabetic micro-and macro-vascular complications (1) , which may account for the disabilities and high mortality rate in patients with this disease (2) .
Microvessels are composed of only two types of cells, endothelial cells and pericytes, and have been known to show both functional and structural abnormalities during prolonged diabetic exposure, resulting in the deleterious effects on the organs that they supply (3) (4) (5) . Using pericyte-endothelial cell co-culture systems, we have shown previously that pericytes can not only regulate the growth but also preserve the prostacyclin-producing ability and protect against lipid peroxide-induced injury of endothelial cells (6) . This has provided a basis for understanding how diabetic retinopathy develops consequent to "pericyte loss," the earliest histopathological hallmark in diabetic retinopathy (5, 7) .
Recently, we have found that AGE exert a growth inhibitory effect and a cell type-specific immediate toxicity on pericytes through interactions with their receptor for AGE (RAGE), a cell surface receptor belonging to the immunoglobulin superfamily (8) , and have proposed a novel mechanism for pericyte loss (9) . The AGE-induced, RAGE-mediated decrease in pericyte number would then indirectly cause angiogenesis (6, 9) .
In the present study, we investigated the effects of AGE on the growth and tube formation of human skin microvascular endothelial cells, the key steps of angiogenesis. We demonstrate that AGE exert angiogenic activities directly on microvascular endothelial cells and that autocrine vascular endothelial growth factor (VEGF) is the major mediator of the AGEdriven angiogenesis.
CL-4B was from Pharmacia LKB (Uppsala, Sweden Preparation of AGE-Proteins and Amadori Compounds-BSA (fraction V, fatty acid-free, free endotoxin) was incubated with 0.5 M glucose at 37°C for 6 weeks under sterile conditions in the presence of 1.5 mM phenylmethylsulfonyl fluoride, 0.5 mM EDTA, 100 units/ml penicillin, and 40 g/ml gentamycin (9 -11). After unincorporated sugars were removed by dialysis against phosphate-buffered saline, glucose-modified high molecular weight materials were purified by heparin-Sepharose CL-4B column chromatography and used as AGE-BSA. Control nonglycated BSA was incubated in the same conditions except for the absence of glucose. The concentration of AGE-BSA was determined by the method of Bradford (12) . AGE-RNase A and AGE-Hb were prepared according to the method of Makita et al. (13) . For reducing AGE-Hb, NaBH 4 was employed as described by Horiuchi et al. (14) . 1-Deoxy-1-propylamino-D-fructose, an Amadori compound, was synthesized by the method of Micheel and Hagemann (15) . N ␣ -Tosyl-N ⑀ -carboxymethyllysine methyl ester (CM-TsLME) was synthesized from N ␣ -tosyl-lysine methyl ester by the method of Ahmed et al. (16) with minor modifications. N-Carboxymethylated BSA (CM-BSA) was prepared according to the method of Reddy et al. (17) .
Preparation of Anti-AGE-RNase A Antiserum-1 mg of AGE-RNase A was emulsified in 50% Freund complete adjuvant and injected intradermally into rabbits. Two weeks later, a booster with the same amount of AGE-RNase A was administered, followed by nine additional booster injections, with one given every 2-3 weeks. Ten days after the final injection, the antiserum was obtained.
Enzyme-linked Immunosorbent Assay (ELISA)-In the noncompetitive ELISA system, wells of 96-well microtiter plates were coated with increasing amounts of Hb, AGE-Hb, and reduced AGE-Hb. After washing and blocking, the wells were incubated with 100 l of anti-AGE antiserum (1:4000) for 2 h and then with 100 l of HRP-conjugated goat anti-rabbit IgG (1:2000) for 30 min. Finally, 100 l of substrate tetramethylbenzidine solution was added into each well. After 10 -15 min, the absorbance at 450 nm was measured. In the competitive ELISA system, procedures similar to the noncompetitive ELISA were used except for the following two points. Wells were first coated with reduced 100 ng/ml AGE-Hb solution as absorbent antigens, and then 50 l of test samples were added as a competitor together with 50 l of anti-AGE antiserum (1:2000) into each well.
Cells-Endothelial cells from human skin microvessels were maintained in E-BM medium supplemented with 5% fetal bovine serum, 0.4% bovine brain extracts, 10 ng/ml human epidermal growth factor, and 1 g/ml hydrocortisone according to the supplier instructions (Clonetics Corp., San Diego, CA). Cells at 5-10 passages were used for the experiments. AGE treatment was carried out in a medium lacking epidermal growth factor and hydrocortisone.
Measurement of Cell Growth-Endothelial cells cultured for various time periods in the presence or absence of AGE-BSA were dislodged with trypsin, and counted by the dye exclusion method (18) . [ 3 H]Thymidine incorporation was determined as described previously (19) . For determining the effects of anti-AGE antiserum on endothelial cell growth, the antiserum was added to the medium at 1% (v/v) together with or without 50 g/ml AGE-BSA, after which cells were incubated for 24 h and [ 3 H]thymidine incorporation was measured. Primers and Probes-Oligonucleotide primers and probes for quantitative reverse transcription-polymerase chain reactions (RT-PCR) were synthesized by a Perkin-Elmer 392 DNA synthesizer (Foster City, CA) and purified as described previously (20) . Primer sequences and internal oligonucleotide probes for detecting VEGF, fms-like tyrosine kinase 1 (flt 1), kinase insert domain-containing receptor (kdr), and ␤-actin mRNA were the same as described in Ref. 20 .
Quantitative RT-PCR-Poly(A) ϩ RNAs were isolated (21) from cells treated with or without AGE-BSA for the various time periods and analyzed by RT-PCR as described previously (22) . 6-l aliquots of each RT-PCR reaction mixture were electrophoresed on a 2% agarose gel and transferred to a Hybond-N ϩ nylon membrane, and the membrane was hybridized with the respective 32 P-end-labeled probes (20) . The amounts of poly(A) ϩ RNA templates (30 ng) and cycle numbers (30 cycles) for amplification were chosen in quantitative ranges where reactions proceeded linearly, which had been determined by plotting signal intensities as functions of the template amounts and cycle numbers (20) . Signal intensities of hybridized bands were measured by a Fujix BAS 1000 Image analyzer (Fuji Photo Film Co. Ltd., Hamamatsu, Japan).
Metabolic Labeling and Immunoprecipitation of VEGF-Subconfluent cultures of endothelial cells were incubated in the presence or absence of 50 g/ml AGE-BSA for 2 h and further incubated for 6 h at 37°C in methionine-free RPMI 1640 medium/complete RPMI 1640 medium (9:1) containing 0.2 mCi/ml [
35 S]methionine with or without AGE-BSA. Immunoprecipitation was carried out as described previously (20) . The samples were analyzed on a 15% SDS-polyacrylamide gel under reducing conditions.
Preparation of Monoclonal Antibody (MoAb) against Human VEGFPeripheral blood lymphocytes from healthy volunteers were immortalized by Epstein-Barr virus, and the resultant Epstein-Barr virus-transformants were screened (23) for their ability to produce antibody molecules that bind to recombinant human VEGF 165 (Peprotech, Rocky Hill, NJ). The candidate cells were then fused with SHM-D33 human myeloma cells (American Type Culture Collection, Rockville, MD). A cell line that consistently produced an IgM-MoAb reactive to VEGF was cloned and designated BL-2. Then the BL-2 MoAb was purified from the serum-free supernatant by 50% ammonium sulfate precipitation and by Sephadex G-200 gel chromatography. The specific binding of MoAb BL-2 to VEGF was confirmed by immunoblotting. 2 Tube Formation in Vitro-Wells of 24-well culture cluster dishes (Coster 3524, Cambridge, MA) were coated with Matrigel solution (250 l/well) and then allowed to solidify for at least 1 h at 37°C (24, 25) . Endothelial cells (4 ϫ 10 4 cells/well) were then seeded on Matrigel with or without 10 g/ml MoAb BL-2. After 30 min, the cells were treated with or without 50 g/ml AGE-BSA for 6 h, 4 microscopic fields selected at random were photographed, and the lengths of tube-like structures were measured with microcomputer-assisted NIH Image (Version 1.56).
RESULTS
Characterization of AGE-BSA-AGE-BSA was prepared by incubating BSA with glucose and then purified by heparinSepharose CL-4B column chromatography. Fig. 1 shows its electrophoretic profile on reducing SDS-polyacrylamide gel electrophoresis. Control nonglycated BSA migrated to the position at 68 kDa. On the other hand, the purified materials migrated much more slowly, yielding a broad band larger than 68 kDa. This indicated that covalently linked adducts were formed nonenzymatically on BSA without discernible degrada- tion. As shown in Table I , the purified materials also exhibited spectrophotometric features characteristic to AGE (26, 27) . The peak fluorescence was noted at 440 nm with excitation at 370 nm, and its intensity was increased 10-fold in comparison with nonglycated BSA. Chromogen products also appeared in the purified materials, whereas they were barely detectable in nonglycated BSA. Based on these observations, the purified materials were used as AGE-BSA.
Characterization of Anti-AGE Antiserum-As a tool to evaluate AGE and their biological effects, an antiserum was raised against AGE-RNase A. The reactivity of this antiserum to several AGE-modified proteins, Amadori compounds, and carboxymethyllysine derivatives was examined. Since it was possible that AGE-modified proteins might contain early glycation products, the immunoreactivity of the antiserum to reduced AGE-Hb was also tested because the early glycation products are known to be converted to glucitol-lysine by reduction with NaBH 4 (14, 28) . As shown in Fig. 2A , there was no difference in the immunoreactivity in the noncompetitive ELISA between AGE-Hb and reduced AGE-Hb. Further, as shown in Fig. 2B , the antiserum binding to AGE-Hb was not competed for by 1-deoxy-1-propylamino-D-fructose in the competitive ELISA, indicating that the antiserum does not recognize Amadori compounds. We next tested whether the antiserum reacted to CMTsLME and CM-BSA in the competitive ELISA. As shown in Fig. 2 , B and C, these glycoxidative products were found to partially inhibit the antiserum binding to reduced AGE-Hb, whereas AGE-Hb and AGE-RNase A fully inhibited its binding (Fig. 2D) . Further, the antiserum reactivity to AGE-BSA was dependent on the duration of incubation of BSA with glucose ( Fig. 2E) . These results suggested that the antiserum could recongnize AGE structures common to various AGE preparations.
FIG. 2. Characterization of anti-AGE antiserum.
A, antiserum was titered in noncompetitive ELISA using Hb (E), AGE-Hb (q), and reduced AGE-Hb (å) as absorbent antigens, as described under "Experimental Procedures." The amounts of the antigens are indicated on the abscissa, and absorbance at 450 nm is on the ordinate. B-D, antiserum was titered in competitive ELISA. Wells were coated with reduced AGE-Hb and then various test samples as competitor, and anti-AGE antiserum were added. B, 1-deoxy-1-propylamino-D-fructose (q); CM-TsLME (E). C, CM-BSA (q); 8-week incubated AGE-BSA (E). D, Hb (E); 8-week incubated AGE-Hb (q); 8-week incubated AGE-RNase A (å). E, BSA (E); 4-week incubated AGE-BSA (q); 8-week incubated AGE-BSA (å); 12-week incubated AGE-BSA (f). The amounts of the competitors are indicated on the abscissa, and absorbance at 450 nm is on the ordinate. Similar results were obtained in two independent experiments. 
Stimulation of the Growth of Microvascular Endothelial
Cells by AGE-Endothelial cells obtained from human skin microvessels were cultured in the presence or absence of AGE-BSA, and the viable cell number was determined at days 1, 2, and 3 after the AGE addition. As shown in Fig. 3 , AGE-BSA was found to increase the viable microvascular endothelial cell number in a dose-dependent manner; at 50 g/ml AGE, there was about a 40% increase in viable cell number. Moreover, AGE-BSA significantly increased DNA synthesis in microvascular endothelial cells to 130% ( p Ͻ 0.01, Fig. 4 ). However, nonglycated BSA induced no change in either the cell number or DNA synthesis.
Neutralization of the AGE-induced DNA Synthesis by Anti-AGE Antibody-To evaluate the specificity of the AGE-BSA effect on endothelial cell growth, we examined the effects of the antiserum against AGE-RNase A on AGE-induced DNA synthesis. As shown in Fig. 4 , the anti-AGE-RNase A antiserum was found to completely neutralize the AGE-induced synthesis of endothelial cell DNA at 1%, while the same concentration of the antiserum did not affect DNA synthesis in endothelial cells not exposed to AGE-BSA.
Microvascular Endothelial Cells Express mRNA for Secretory Forms of VEGF in Response to AGE-Poly(A)
ϩ RNAs were isolated from microvascular endothelial cells treated with various concentrations of AGE-BSA for various time periods, and analyzed by a quantitative RT-PCR technique to determine the effects of AGE on the expression of the VEGF gene. It has been reported that there are four alternatively spliced products from the single VEGF gene, VEGF 121 , VEGF 165 , VEGF 189 , and VEGF 206 (29, 30) . Since Northern blot analysis cannot clearly discriminate the four mRNA species, we employed a more sensitive RT-PCR technique as described previously (20) . In this experiment, 486-and 618-base pairs (bp)-long cDNA products would be amplified from mRNAs for VEGF 121 and VEGF 165 , respectively (20) .
As shown in Fig. 5, A and B, microvascular endothelial cells were expressing mRNAs for VEGF 121 and VEGF 165 , the secretory forms of VEGF. When the endothelial cells were exposed to AGE-BSA, the level of VEGF mRNAs was found to be significantly increased in a time-and dose-dependent manner. The VEGF mRNA level began to increase at 2 h, and reached a maximum at 4 h in the presence of 50 g/ml AGE-BSA; the peak value was 3-fold higher than the basal level when standardized with the signal intensities of ␤-actin mRNA as an internal control. Maximal stimulation was achieved at 50 -100 g/ml AGE. However, the larger alternatively spliced products coding for VEGF 189 and VEGF 206 were not detected in microvascular endothelial cells regardless of the presence or absence of AGE-BSA.
To confirm whether AGE-BSA increased the synthesis of VEGF proteins, we performed immunoprecipitation using the anti-VEGF monoclonal antibody (20) from lysates of the cells that had been treated with or without AGE-BSA. As shown in Fig. 5C , 35 S-labeled proteins that migrated to the positions of 18 and 22 kDa, corresponding to VEGF 121 and VEGF 165 , respectively, were immunoprecipitated, and the amounts of these proteins were found to be increased to about 2.5-fold by the AGE treatment.
VEGF Receptor Expressions in Microvascular Endothelial
Cells-VEGF exerts its biological actions through its specific receptors, KDR and Flt 1 (31, 32) . We then determined the types of VEGF receptors expressed in microvascular endothelial cells and whether their expressions could be altered by AGE-BSA. As shown in Fig. 5B , both kdr and flt 1 mRNA were detected in microvascular endothelial cells, and the content of kdr mRNA was more abundant than that of flt 1 mRNA. In contrast to VEGF mRNAs, the levels of the two types of receptors were essentially unchanged by the exposure to AGE-BSA. concentrations of MoAb BL-2 for 30 min, then exposed to 50 g/ml AGE-BSA for 24 h in the presence of the antibody, and assayed for [ 3 H]thymidine incorporation. As shown in Fig. 6 , MoAb BL-2 was found to significantly diminish the AGE-induced increase in DNA synthesis in a dose-dependent manner; at 10 g/ml, a complete reversal was obtained. The MoAb alone did not affect DNA synthesis in endothelial cells not exposed to AGE.
Neutralization of the AGE-Induced DNA Synthesis of Microvascular Endothelial Cells by MoAb against

AGE Induction of Tube Formation of Microvascular Endothelial Cells and Its Inhibition by Anti-VEGF MoAb-
The process of angiogenesis has been assumed to be completed by the formation of microvascular tubes (19) . In vitro assays for tube formation of endothelial cells have been developed and used to study this crucial step of angiogenesis. Accordingly, we examined whether AGE affect in vitro tube formation of microvascular endothelial cells. For this, we employed an on-gel assay system using Matrigel, in which endothelial cells take only several hours to associate with each together and form microtubes. Microvascular endothelial cells were seeded on Matrigel with or without AGE-BSA, and tube formations were judged after 6 h. As shown in Fig. 7A , AGE-BSA was found to double the length of the tubes of endothelial cells formed on Matrigel; and, the AGE-induced tube formation was inhibited by BL-2 MoAb as was the AGE-induced DNA synthesis of endothelial cells. The MoAb per se did not affect the tube formation. Fig. 7B shows typical micrographs; with 10 g/ml BL-2 MoAb, AGEinduced tube formation was markedly inhibited.
DISCUSSION
In the present study, we have demonstrated for the first time that AGE, nonenzymatically glycated protein derivatives formed under hyperglycemia, stimulate the growth and tube formation of human microvascular endothelial cells, the key steps of angiogenesis which take place in this very cell type (33, 34) . The present findings have extended our preliminary work employing endothelial cells from a larger vessel, i.e. the umbilical vein. Though modestly, AGE-BSA caused a consistent increase in cell number and in DNA synthesis of both umbilical and microvasular endothelial cells, the same AGE-BSA concentration (50 g/ml) giving the maximal effect in both cases (35) . ϩ RNAs from endothelial cells treated with the various concentrations of AGE were reverse transcribed, and PCR was performed for 25 cycles. The PCR products were electrophoresed on 2% agarose gel, transferred onto nylon membranes, and hybridized with 32 P-endlabeled probes. PCR amplification for ␤-actin mRNA was performed for 20 cycles. Size markers (bp) are shown on the left. C, VEGF synthesis in AGE-treated and untreated endothelial cells. Immunoprecipitation was carried out as described under "Experimental Procedures." Immunoreacted materials that had been prepared from 8.0 ϫ 10 6 dpm of lysates were electrophoresed on a 15% SDS-polyacrylamide gel under reducing conditions. The gel was dried and autoradiographed. The radioactivities of the bands were measured with a Fujix BAS 1000 BioImage analyzer. Specific immunoprecipitates were marked at 22 and 18 kDa. Similar results were obtained in two independent experiments. This concentration of AGE was comparable with that of the in vivo situation in diabetes; Makita et al. reported (13) that human serum AGE levels were elevated more than 2-fold in diabetic patients (about 25 g/ml) and almost 8-fold in diabetic patients on hemodialysis (about 80 g/ml) in comparison with that in normal patients.
That it was AGE moieties that elicited the angiogenic activity was evidenced as follows. First, the AGE-BSA employed exhibited the biochemical hallmarks of AGE ( Fig. 1 and Table  I ). Second, control nonglycated BSA made no change (data not shown). Third, a newly developed antiserum against AGERNase A could neutralize the growth-promoting effect of AGE-BSA (Fig. 4) . Although this antiserum was partially reactive to carboxymethyllysine, it would seem unlikely that the AGE effect could be accounted for by such glycoxidative biproducts of the Maillard reaction, which might be present in trace amounts in the AGE-BSA preparation, because authentic carboxymethylated BSA added to the culture medium at concentrations from 1 to 100 g/ml failed to stimulate the endothelial cell synthesis of DNA (data not shown). We speculate that the AGE actions on microvascular endothelial cells may require their binding to RAGE, the AGE-specific receptor, as is the case with bovine retinal pericytes (9), human umbilical vein endothelial cells (35) , and human pancreatic cancer cells (36) .
The present study has also demonstrated that the angiogenic activity of AGE is mainly mediated by autocrine VEGF synthesized by micrcovascular endothelial cells per se. mRNAs for VEGF 121 and VEGF 165 are present in microvascular endothelial cells, and their levels are up-regulated by AGE in both dose-and time-dependent manners (Fig. 5, A and B) . AGE did increase de novo synthesis of VEGF in endothelial cells (Fig.  5C) . mRNAs for the two VEGF receptors, kdr and flt 1, were also detected in human skin microvascular endothelial cells, their relative abundance being kdr Ͼ Ͼ flt 1. However, their levels were essentially unaltered when exposed to AGE (Fig.  5B ). This suggests that the ligand expression should be the rate-limiting step in the putative autocrine action of VEGF. In effect, the neutralization experiments established the functional role of VEGF in the AGE-induced endothelial cell growth and tube formation. MoAb against human VEGF could completely inhibit the AGE-induced tube formation as well as the DNA synthesis of microvascular endothelial cells (Figs. 6 and   7 ). Since the basal growth or tube formation in unexposed cells was not affected by the same concentration of the antibody, the antibody-induced inhibition is not likely the result of its toxic or nonspecific effects. These results thus indicate that autocrine VEGF is the main mediator of the AGE-driven angiogenesis in vitro.
In light of the present findings, together with the previous observations, we can now posit an overall scheme concerning the roles of AGE in the development of diabetic microangiopathy (Fig. 8) . First, AGE act on pericytes, the microvascular constituent that encircles the endothelium. Through interactions with RAGE, AGE decrease the number of this cell type (9), leading to pericyte dropout, which would in turn relieve the restriction on endothelial cell replication and facilitate angiogenesis. The resultant cessation of pericyte-endothelial cell interactions would impair prostacyclin production (6), which would cause thrombogenesis. Second, AGE act on endothelial cells, which serve as a barrier between circulating blood and parenchyma and produced various vasoactive substances. As shown in this paper, one consequence is angiogenesis that is probably mediated by autocrine VEGF. In addition, the prostacyclin-synthesizing ability of microvascular endothelial cells might be directly inhibited by AGE, as in umbilical endothelial cells (35) . Again, the consequence of this would be thrombogenesis. Diminished circulation or microthrombus formation may occur in such lesions, giving rise to hypoxia, the major factor triggering VEGF expression in both endothelial cells and pericytes (20, (37) (38) (39) (40) . In such circumstances, angiogenesis would further proceed, which may eventually lead to the clinical expression of diabetic microangiopathies, exemplified by proliferative retinopathy. According to this model, procedures that can halt those events, e.g. inhibition of AGE formation, 3 AGE absorption by immobilized antibodies, antisense RAGE DNA (35, 36) , prostacyclin analogues, or anti-VEGF neutralizing antibodies would then theoretically help circumvent the development and progression of diabetic microangiopathies.
Although this view basically stands on the in vitro experiments, in support are several in vivo or clinical observations. Hammes et al. (41, 42) reported that aminoguanidine, an inhibitor of AGE formation, prevented AGE accumulation at branching sites of precapillary arterioles and that this inhibitor could diminish pericyte dropout and inhibit abnormal endothelial cell proliferation in streptozotocin-induced diabetic rats. Dolhofer-Bliesener et al. (43) have shown that, in human diabetic subjects, the serum level of AGE was associated with the state of late complications, particularly in cases with retinopathy. Wautier et al. (44) reported that infusion of diabetic red blood cells into normal rats can induce vascular hyperpermeability, which was completely inhibited by anti-RAGE IgG; they also demonstrated that an antioxidant, probucol, can similarly reverse the red blood cell transfer-induced vascular permeability, suggesting a role of AGE-RAGE interactions and the involvement of an oxidant stress-sensitive pathway in the development of hyperpermeability. Recent clinical studies at different institutions have established that intraocular concentrations of VEGF correlated with active neovascularization (45, 46) . Further, the increased permeability of retinal capillaries and the breakdown of the blood-retinal barrier have been shown to be as an early event in both human diabetic subjects and streptozotocin diabetic rats followed by new vessel formation (47, 48) . The barrier breakdown would help ensure pericyte access to AGE. Moreover, it is reported that the barrier breakdown could be protected by the treatment of aminoguanidine, suggesting that AGE themselves may be directly involved in the barrier breakdown (48) .
